Advanced Search

 

Study ID Status Title Patient Level Data
ARI40001 Completed A multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy of GI198745 0.5mg Once Daily versus finasteride 5mg Once Daily for 12 months in the treatment of subjects with benign prostatic hyperplasia (BPH). (EPICS) Study Listed on ClinicalStudyDataRequest.com
ARI40001_1 Completed A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Group Study to Compare the Efficacy of Dutasteride/GI198745 0.5mg Once Daily Versus Finasteride 5mg Once Daily for 12 Months in the Treatment of Subjects with Benign Prostatic Hyperplasia (BPH), Followed by an Optional 24 Months Open Label Phase. Study Listed on ClinicalStudyDataRequest.com
ARI40002 Completed A pilot multi-centre, double-blind, parallel group, randomised study to investigate the effect on symptoms 3 months after discontinuing tamsulosin, following 6 months combination treatment with 0.5mg GI198745 and 0.4mg tamsulosin daily in patients with symptomatic Benign Prostatic Hyperplasia (BPH). Study Listed on ClinicalStudyDataRequest.com
ARI40005 Completed A randomized, double-blind, parallel group study to investigate the efficacy and safety of treatment with dutasteride (0.5mg) and tamsulosin (0.4mg), administered once daily for 4 years, alone and combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARI40006 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer Study Listed on ClinicalStudyDataRequest.com
ARI40007 Completed A randomised, double-blind, placebo-controlled, parallel group study investigating the effects of either 4 or 6 weeks dutasteride 0.5mg daily on peri-operative bleeding following transurethral resection of the prostate (TURP) in subjects with benign prostatic hyperplasia (BPH). Study Listed on ClinicalStudyDataRequest.com
ARI40010 Completed Multicenter, double-blind, randomized, parallel-group study, comparing 0.5 mg and 3.5 mg dutasteride daily for 4 months prior to radical prostatectomy versus radical prostatectomy alone in men with biopsy-proven and clinically localized prostate cancer Study Listed on ClinicalStudyDataRequest.com
ARI40014 Completed Effects of Dutasteride on Intraprostatic Dihydrotestosterone (DHT) Levels Study Listed on ClinicalStudyDataRequest.com
ARIA1009 Completed An Investigation of the Pharmacokinetics of GI198745 and of the Effects of GI198745 on Semen Characteristics When Administered Daily for 12 Months to Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
ARIA1012 Completed Investiagtion of the Metabolic Fate and Routes of Excretion of GI198745 at Steady State in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
ARIA2003 Completed A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety And Preliminary Efficacy of Neoadjuvant Therapy With GI198745 in Subjects With Localized Prostate Cancer Undergoing Radical Prostatectomy. Study Listed on ClinicalStudyDataRequest.com
ARIA3001_1 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Year 1 Data) Study Listed on ClinicalStudyDataRequest.com
ARIA3001_2 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data). Study Listed on ClinicalStudyDataRequest.com
ARIA3001_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel Group Study of the Efficacy and Safety of Dutasteride GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIA3002 Completed A Randomized, double-blind, placebo-controlled, two year parallel group study of the efficacy and safety of GI198745 0.5 mg in the treatment and prevention of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIA3002_2 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on 2 Year Data). Study Listed on ClinicalStudyDataRequest.com
ARIA3002_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two Year Parallel Group Study of the Efficacy and Safety of GI198745 0.5mg in the Treatment and Prevention of Progression of Benign Prostatic Hyperplasia, Followed by a Two-Year Open-Label Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB3003 Completed A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of GI198745 in the treatment and modification of progression of benign prostatic hyperplasia Study Listed on ClinicalStudyDataRequest.com
ARIB3003_4 Completed A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression of Benign Prostatic Hyperplasia, Followed by a Two Year Open-Label GI198745 Treatment Phase (Report on Open-Label Treatment Phase). Study Listed on ClinicalStudyDataRequest.com
ARIB3004 Completed A six-month, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effects of repeat dose oral GI198745 on detrusor pressure and urinary flow in patients with lower urinary tract symptoms suggestive of bladder outlet obstruction, with optional six month open-label extension Study Listed on ClinicalStudyDataRequest.com
ARIB3004_1 Completed A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effects of Repeat Dose Oral Dutasteride GI198745 on Detrusor Pressure and Urinary Flow in Patients with Lower Urinary Tract Symptoms Suggestive of Bladder Outlet Obstruction, with Optional Six Month Open-Label Extension. Study Listed on ClinicalStudyDataRequest.com
AUG102821 Completed A study to determine PK profiles of AUGMENTIN XR in adolescents weight at least 40 kg receiving Augmentin XR BID for 10 days Study Listed on ClinicalStudyDataRequest.com
AVA102670 Completed A 54 week, double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE4-stratified subjects with mild to moderate Alzheimer's disease Study Listed on ClinicalStudyDataRequest.com
AVA102672 Completed A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease. Study Listed on ClinicalStudyDataRequest.com
AVA102675 Terminated An open-label extension to study AVA102670 and AVA102672, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) as adjunctive therapy on cognition in subjects with mild to moderate Alzheimer's disease. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.